Real-world safety of nusinersen in Japan: results from an interim analysis of a post-marketing surveillance and safety database

References

• Farooq FT, Holcik M, MacKenzie A. Spinal muscular atrophy: classification, diagnosis, background, molecular mechanism and development of therapeutics. In: Kishore U, editor. Neurodegenerative diseases. InTechOpen; 2013.
   Google Scholar
• Sugarman EA, Nagan N, Zhu H, et al. Pan-ethnic carrier screening and prenatal diagnosis for spinal muscular atrophy: clinical laboratory analysis of >72,400 specimens. Eur J Hum Genet. 2012;20(1):27–32.
   PubMed Web of Science ®Google Scholar
• Lefebvre S, Burglen L, Reboullet S, et al. Identification and characterization of a spinal muscular atrophy-determining gene. Cell. 1995;80(1):155–165.
   PubMed Web of Science ®Google Scholar
• Arkblad E, Tulinius M, Kroksmark AK, et al. A population-based study of genotypic and phenotypic variability in children with spinal muscular atrophy. Acta Paediatr. 2009;98(5):865–872.
   PubMed Web of Science ®Google Scholar
• Ogino S, Wilson RB, Gold B. New insights on the evolution of the SMN1 and SMN2 region: simulation and Meta-analysis for allele and haplotype frequency calculations. Eur J Hum Genet. 2004;12(12):1015–1023.
   PubMed Web of Science ®Google Scholar
• Finkel R, Bertini E, Muntoni F, ENMC SMA Workshop Study Group, et al. 209th ENMC international workshop: Outcome measures and clinical trial readiness in spinal muscular atrophy 7-9 November 2014, Heemskerk, The Netherlands. Neuromuscul Disord. 2015;25(7):593–602.
   PubMed Web of Science ®Google Scholar
• Calucho M, Bernal S, Alías L, et al. Correlation between SMA type and SMN2 copy number revisited: an analysis of 625 unrelated spanish patients and a compilation of 2834 reported cases. Neuromuscul Disord. 2018;28(3):208–215.
   PubMed Web of Science ®Google Scholar
• Hua Y, Sahashi K, Hung G, et al. Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model. Genes Dev. 2010;24(15):1634–1644.
   PubMed Web of Science ®Google Scholar
• Finkel RS, Chiriboga CA, Vajsar J, et al. Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study. Lancet. 2016;388(10063):3017–3026.
   PubMed Web of Science ®Google Scholar
• Havens MA, Hastings ML. Splice-switching antisense oligonucleotides as therapeutic drugs. Nucleic Acids Res. 2016;44(14):6549–6563.
   PubMed Web of Science ®Google Scholar
• Rigo F, Hua Y, Krainer AR, et al. Antisense-based therapy for the treatment of spinal muscular atrophy. J Cell Biol. 2012;199(1):21–25.
   PubMed Web of Science ®Google Scholar
• Finkel RS, Mercuri E, Darras BT, et al. Nusinersen versus sham control in infantile-onset spinal muscular atrophy. N Engl J Med. 2017;377(18):1723–1732.
   PubMed Web of Science ®Google Scholar
• Mercuri E, Darras BT, Chiriboga CA, et al. Nusinersen versus sham control in later-onset spinal muscular atrophy. N Engl J Med. 2018;378(7):625–635.
   PubMed Web of Science ®Google Scholar
• Mercuri E, Finkel RS, Muntoni F, SMA Care Group, et al. Diagnosis and management of spinal muscular atrophy: Part 1: Recommendations for diagnosis, rehabilitation, orthopedic and nutritional care. Neuromuscul Disord. 2018;28(2):103–115.
   PubMed Web of Science ®Google Scholar
• Frazier KS. Antisense oligonucleotide therapies: the promise and the challenges from a toxicologic pathologist’s perspective. Toxicol Pathol. 2015;43(1):78–89.
   PubMed Web of Science ®Google Scholar
• Haataja L, Mercuri E, Regev R, et al. Optimality score for the neurologic examination of the infant at 12 and 18 months of age. J Pediatr. 1999;135(2 Pt):153–161.
   PubMed Web of Science ®Google Scholar
• WHO Multicenter Growth Reference Study Group. WHO motor development study: windows of achievement for six gross motor development milestones. Acta Paediatr Suppl. 2006;450:86–95.
   PubMedGoogle Scholar
• O’Hagen JM, Glanzman AM, McDermott MP, et al. An expanded version of the hammersmith functional motor scale for SMA II and III patients. Neuromuscul Disord. 2007;17(9–10):693–697.
   PubMed Web of Science ®Google Scholar
• Dunaway Young S, Montes J, Kramer SS, et al. Six-minute walk test is reliable and valid in spinal muscular atrophy. Muscle Nerve. 2016;54(5):836–842.
   PubMed Web of Science ®Google Scholar
• Stull D, Williams V, Houghton K, et al. Minimal clinically important differences in motor function in patients with infantile-onset spinal muscular atrophy: results from the phase 3 ENDEAR trial. J Manag Care Spec Pharm. 2019;25(Suppl. 3-a):S55.
   Google Scholar
• Moore N, Hall G, Sturkenboom M, et al. Biases affecting the proportional reporting ratio (PPR) in spontaneous reports pharmacovigilance databases: the example of sertindole. Pharmacoepidemiol Drug Saf. 2003;12(4):271–281.
   PubMed Web of Science ®Google Scholar
• Busner J, Targum SD. The clinical global impressions scale: applying a research tool in clinical practice. Psychiatry (Edgemont). 2007;4:28–37.
   PubMedGoogle Scholar
• Pariente A, Gregoire F, Fourrier-REglat A, et al. Impact of safety alerts on measures of disproportionality in spontaneous reporting databases: the notoriety bias. Drug Saf. 2007;30(10):891–898.
   PubMed Web of Science ®Google Scholar
• Pera MC, Coratti G, Forcina N, et al. Content validity and clinical meaningfulness of the HFMSE in spinal muscular atrophy. BMC Neurol. 2017;17(1):39.
   PubMed Web of Science ®Google Scholar
• Darras BT, Farrar MA, Mercuri E, et al. An integrated safety analysis of infants and children with symptomatic spinal muscular atrophy (SMA) treated with nusinersen in seven clinical trials. CNS Drugs. 2019;33(9):919–932.
   PubMed Web of Science ®Google Scholar
• Mercuri E, Finkel R, Farrar M, et al. Infants and children with SMA treated with nusinersen in clinical trials: an integrated safety analysis. Neuromuscul Disord. 2017;27(Suppl 2):S210.
   Google Scholar
• Chrysant SG. Proactive compared with passive adverse event recognition: calcium channel blocker-associated edema. J Clin Hypertens (Greenwich). 2008;10(9):716–722.
   PubMed Web of Science ®Google Scholar
• Hache M, Swoboda KJ, Sethna N, et al. Intrathecal injections in children with spinal muscular atrophy: nusinersen clinical trial experience. J Child Neurol. 2016;31(7):899–906.
   PubMed Web of Science ®Google Scholar
• Sand T, Stovner LJ, Dale L, et al. Side effects after diagnostic lumbar puncture and lumbar iohexol myelography. Neuroradiology. 1987;29(4):385–388.
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. Spinraza (nusinersen) injection, for intrathecal use. Prescribing information. 2016. https://www.spinraza.com/content/dam/commercial/specialty/spinraza/caregiver/en_us/pdf/spinraza-prescribing-information.pdf. [Last update June 2020]. Accessed 9 March 2021.
   Google Scholar
• Tozawa T, Kasai T, Tatebe H, et al. Intrathecal nusinersen treatment after ventriculo-peritoneal shunt placement: a case report focusing on the neurofilament light chain in cerebrospinal fluid. Brain Dev. 2020;42(3):311–314.
   PubMed Web of Science ®Google Scholar
• Hagenacker T, Wurster CD, Gunther R, et al. Nusinersen in adults with 5q spinal muscular atrophy: a non-interventional, multicentre, observational cohort study. Lancet Neurol. 2020;19(4):317–325.
   PubMed Web of Science ®Google Scholar
• Walter MC, Drager B, Gunther R, et al. [Treatment evaluation in patients with 5q-associated spinal muscular atrophy : Real-world experience]. Nervenarzt. 2019;90(4):343–351.
   PubMed Web of Science ®Google Scholar
• Pane M, Coratti G, Sansone VA, on behalf of the Italian Expanded Access Program Working Group, et al. Nusinersen in type 1 spinal muscular atrophy: twelve-month real-world data. Ann Neurol. 2019;86(3):443–451.
   PubMed Web of Science ®Google Scholar
• Maggi L, Bello L, Bonanno S, et al. Nusinersen safety and effects on motor function in adult spinal muscular atrophy type 2 and 3. J Neurol Neurosurg Psychiatry. 2020;91(11):1166–1174.
   PubMed Web of Science ®Google Scholar
• Scoto M, Manzur A, Main M, et al. The use of nusinersen in the "real world": the UK and Ireland experience with the expanded access program (EAP). Neuromuscul Disord. 2018;28(Suppl 1):S25.
   Web of Science ®Google Scholar
• Pane M, Coratti G, Sansone VA, the Italian EAP Working Group, et al. Type I SMA “new natural history”: long-term data in nusinersen-treated patients. Ann Clin Transl Neurol. 2021;8(3):548–557.
   PubMed Web of Science ®Google Scholar
• Coratti G, Pane M, Lucibello S, et al. Age related treatment effect in type II spinal muscular atrophy pediatric patients treated with nusinersen. Neuromusc Disord. 2021;31(7):596–602.
   PubMed Web of Science ®Google Scholar
• Pera MC, Coratti G, Bovis F, iSMAC group, et al. Nusinersen in pediatric and adult patients with type III spinal muscular atrophy. Ann Clin Transl Neurol. 2021;8(8):1622–1634.
   PubMed Web of Science ®Google Scholar
• Osredkar D, Jílková M, Butenko T, et al. Children and young adults with spinal muscular atrophy treated with nusinersen. Eur J Paediatr Neurol. 2021;30:1–8.
   PubMed Web of Science ®Google Scholar
• Mercuri E, Finkel R, Scoto M, iSMAC Group, et al. Development of an academic disease registry for spinal muscular atrophy. Neuromuscul Disord. 2019;29(10):794–799.
   PubMed Web of Science ®Google Scholar
• Pechmann A, Konig K, Bernert G, et al. SMArtCARE - A platform to collect real-life outcome data of patients with spinal muscular atrophy . Orphanet J Rare Dis. 2019;14(1):18.
   PubMed Web of Science ®Google Scholar
• Hodgkinson VL, Oskoui M, Lounsberry J, et al. A national spinal muscular atrophy registry for real-world evidence. Can J Neurol Sci. 2020;47(6):810–815.
   PubMed Web of Science ®Google Scholar